33 results on '"Barrio, J. A."'
Search Results
2. P649 Long-term follow-up of the PROTDILAT study; LONG-PROTDILAT Prospective multicenter randomized comparative study of endoscopic treatment of strictures in Crohn's disease (CD): self-expandable metal stent (SEMS) vs endoscopic balloon dilatation (EBD)
3. DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
4. P949 Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study. A multicenter study from the young group of GETECCU
5. P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
6. P643 Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study
7. OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
8. P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry
9. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)
10. P118 Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
11. P122 Low Risk of new dysplastic lesions during inflammatory bowel disease surveillance with dye-cromoendoscopy: a multicenter population-based retrospective study
12. P362 Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring
13. P067 Human intestinal CD103+SIRPα+ conventional dendritic cells from patients with Crohn′s disease prime IL-17+ T-cells
14. P458 Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn’s disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN
15. P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc
16. DOP31 Management and outcome of postoperative Crohn’s Disease in the elderly as compared to young adults: Data from Eneida registry
17. OP20 Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
18. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
19. P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study
20. P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
21. P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
22. P397 Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida Registry
23. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU
24. P666 Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
25. P663 Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
26. P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study
27. P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease
28. P463 Infliximab use in ulcerative colitis from 2003 to 2013: Clinical practice, safety and efficacy
29. P464 Infliximab optimisation in ulcerative colitis: Intensificated and deintensificated patients clinical outcome
30. P530 Effectiveness of anti-TNF drugs in Crohn's disease (CD) patients who did not achieve remission with the first anti-TNF
31. P438 Multicenter prospective observational study to assess the impact of surveillance, prophylaxis or treatment of the hepatitis B (HBV) and C (HCV) virus infection in patients with inflammatory bowel disease (IBD) under anti-TNF therapies
32. P134 Is faecal calprotectin a useful marker of postoperative recurrence in Crohn's ileal disease?
33. P312 Quick schedule and double dose vaccination against hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.